Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche's wager is that Promedior's PRM-151 can become its next big fibrosis drug as Esbriet's orphan exclusivity ends in 2021; Phase 2 data showed significantly…
Roche framed the Promedior buyout as expanding its fibrotic disease pipeline, with PRM-151 a recombinant pentraxin-2 already in late-stage Phase 2 in IPF and…
Promedior CEO Jason Lettmann: "Due to Roche's strong expertise in IPF, hematological cancer and other fibrotic disorders, we believe Roche is ideally…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Roche exercised its option to acquire Promedior for $390M upfront plus up to $1B in contingent payments tied to regulatory and commercial milestones. Lead asset PRM-151 is a recombinant pentraxin-2 in Phase 2 for idiopathic pulmonary fibrosis and myelofibrosis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Promedior, Inc. (this deal) | 2019 | $1.4B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Hematology deals